BACKGROUND: Prepulse inhibition (PPI) of startle is a measure of sensorimotor gating that is deficient in certain psychiatric disorders, including schizophrenia. Sprague Dawley (SD) rats are more sensitive to PPI-disruptive effects of apomorphine (APO) at long interstimulus intervals (ISIs) (60-120 msec) and less sensitive to PPI-enhancing effects of APO at short ISIs (10-30 msec) compared with Long Evans (LE) rats. METHODS: Prepulse inhibition was tested in SD and LE rats after APO (.5 mg/kg) or vehicle in a within- subject design and sacrificed 14 days later. Total RNA was extracted from the nucleus accumbens (NAC). Approximately 700 dopamine-relevant transcripts on the Affymetrix 230 2.0 microarray were analyzed. RESULTS: As previously reported, SD rats exhibited greater APO-induced PPI deficits at long intervals and less APO-induced PPI enhancement at short intervals compared with LE rats. One hundred four genes exhibited significantly different NAC expression levels in these two strains. Pathway analysis revealed that many of these genes contribute to dopamine receptor signaling, synaptic long-term potentiation, or inositol phosphate metabolism. The expression of some genes significantly correlated with measures of APO-induced PPI sensitivity in either SD or LE rats. The expression of select genes was validated by real-time reverse transcription polymerase chain reaction (RT-PCR). CONCLUSIONS: Differences in PPI APO sensitivity in SD versus LE rats are robust and reproducible and may be related to strain differences in the expression of genes that regulate signal transduction in the NAC. These genes could facilitate the identification of targets for ameliorating heritable gating deficits in brain disorders such as schizophrenia.
BACKGROUND: Prepulse inhibition (PPI) of startle is a measure of sensorimotor gating that is deficient in certain psychiatric disorders, including schizophrenia. Sprague Dawley (SD) rats are more sensitive to PPI-disruptive effects of apomorphine (APO) at long interstimulus intervals (ISIs) (60-120 msec) and less sensitive to PPI-enhancing effects of APO at short ISIs (10-30 msec) compared with Long Evans (LE) rats. METHODS: Prepulse inhibition was tested in SD and LE rats after APO (.5 mg/kg) or vehicle in a within- subject design and sacrificed 14 days later. Total RNA was extracted from the nucleus accumbens (NAC). Approximately 700 dopamine-relevant transcripts on the Affymetrix 230 2.0 microarray were analyzed. RESULTS: As previously reported, SD rats exhibited greater APO-induced PPI deficits at long intervals and less APO-induced PPI enhancement at short intervals compared with LE rats. One hundred four genes exhibited significantly different NAC expression levels in these two strains. Pathway analysis revealed that many of these genes contribute to dopamine receptor signaling, synaptic long-term potentiation, or inositol phosphate metabolism. The expression of some genes significantly correlated with measures of APO-induced PPI sensitivity in either SD or LE rats. The expression of select genes was validated by real-time reverse transcription polymerase chain reaction (RT-PCR). CONCLUSIONS: Differences in PPI APO sensitivity in SD versus LE rats are robust and reproducible and may be related to strain differences in the expression of genes that regulate signal transduction in the NAC. These genes could facilitate the identification of targets for ameliorating heritable gating deficits in brain disorders such as schizophrenia.
Authors: N R Swerdlow; A Platten; Y K Kim; I Gaudet; J Shoemaker; L Pitcher; P Auerbach Journal: Pharmacol Biochem Behav Date: 2001 Oct-Nov Impact factor: 3.533
Authors: Kim Cryns; Alon Shamir; Joseph Shapiro; Gie Daneels; Ilse Goris; Hansfried Van Craenendonck; Roel Straetemans; R H Belmaker; Galila Agam; Dieder Moechars; Thomas Steckler Journal: Neuropsychopharmacology Date: 2006-07-12 Impact factor: 7.853
Authors: Neal R Swerdlow; Jody M Shoemaker; Michele J Bongiovanni; Alaina C Neary; Laura S Tochen; Richard L Saint Marie Journal: Pharmacol Biochem Behav Date: 2007-04-03 Impact factor: 3.533
Authors: Neal R Swerdlow; Susan B Powell; Michelle R Breier; Samantha R Hines; Gregory A Light Journal: Neuropharmacology Date: 2013-06-26 Impact factor: 5.250
Authors: Neal R Swerdlow; Paul D Shilling; Michelle Breier; Ryan S Trim; Gregory A Light; Richard Saint Marie Journal: Psychopharmacology (Berl) Date: 2012-06-15 Impact factor: 4.530
Authors: Neal R Swerdlow; Martin Weber; Ying Qu; Gregory A Light; David L Braff Journal: Psychopharmacology (Berl) Date: 2008-06-21 Impact factor: 4.530
Authors: Michelle R Breier; Brittanni Lewis; Jody M Shoemaker; Gregory A Light; Neal R Swerdlow Journal: Behav Brain Res Date: 2010-01-18 Impact factor: 3.332
Authors: Neal R Swerdlow; Sophia A Lelham; Ashley N Sutherland Owens; Wei-Li Chang; Sebastiaan D T Sassen; Jo A Talledo Journal: Psychopharmacology (Berl) Date: 2009-06-09 Impact factor: 4.530